Time trends in incidence and mortality of cutaneous melanoma in Germany
Objectives To characterize incidence and mortality trends of cutaneous melanoma (CM) in Germany to extrapolate these data until 2030. Methods We evaluated data from the Centre for Cancer Registry Data (1999–2012) and from the Saarland Cancer Registry (1970–2012). Age‐standardized (according to the E...
Gespeichert in:
Veröffentlicht in: | Journal of the European Academy of Dermatology and Venereology 2019-07, Vol.33 (7), p.1272-1280 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Objectives
To characterize incidence and mortality trends of cutaneous melanoma (CM) in Germany to extrapolate these data until 2030.
Methods
We evaluated data from the Centre for Cancer Registry Data (1999–2012) and from the Saarland Cancer Registry (1970–2012). Age‐standardized (according to the European Standard Population, WHO 1976) incidence and mortality rates [age‐standardized incidence rates (ASIRs) and age‐standardized mortality rates (ASMRs)] and crude incidence and mortality rates [crude incidence rates (CIRs) and crude mortality rates (CMRs)] were analysed.
Results
In entire Germany, ASIRs increased by 55% to 19.2 and CIRs by 77% to 26.0 new cases per 100 000 from 1999 to 2012. ASMRs remained stable, whereas CMR increased by 58% to 4.1 for males and by 30% to 3.0 for females per 100 000. In the Federal State of Saarland, ASIRs increased more than four‐fold to 13.1, CIRs increased six–seven fold to 18.5/100 000 from 1970 to 2012. In the same period, ASMRs increased three‐fold in males and two‐fold in females to 2.5 and 1.6, whereas CMRs increased 5.5‐fold in males and 3.5‐fold in females to 3.9 and 3.2/100 000, mainly caused by steep increases of CIRs and CMRs in age groups ≥60 years. Projected CIRs will rise to 44–46 for males and 38–40 for females in 2030. Steepest increases were extrapolated for patients ≥60 years, especially for males, but are also expected for age groups of 40–59 years. In contrast, CIRs are anticipated to stabilize for subjects |
---|---|
ISSN: | 0926-9959 1468-3083 |
DOI: | 10.1111/jdv.15322 |